Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc (COLL) is a specialty pharmaceutical company focused on prescription pain therapies, best known for Xtampza ER — an extended‑release oxycodone product with abuse‑deterrent properties. With a market cap around $1.11bn, Collegium generates revenue from branded opioid products and related licensing or distribution arrangements. Key considerations for investors include reliance on a narrow product portfolio, exposure to regulatory scrutiny over opioid prescribing and reimbursement, and potential competition from generics. The company has pursued lifecycle management, patent protection and commercial partnerships to support sales, but future growth depends on market access, prescriber adoption and legal outcomes. Collegium may suit investors seeking exposure to niche pharmaceutical franchises but carries company‑specific and sector risks; this is general information and not personalised investment advice. Values can fall as well as rise, and past performance is not a guide to the future.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Collegium Pharmaceutical's stock, which has a target price of $46.8.
Financial Health
Collegium Pharmaceutical Inc is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring COLL
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketBeyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Product-led growth
Xtampza ER and related branded therapies can support sales growth if prescribing and payer coverage improve, though outcomes depend on uptake and market access.
Regulatory sensitivity
Policy shifts on opioids, approval decisions and label changes can meaningfully affect prospects — regulatory risk is an important watchpoint.
Competition & litigation
Patent protection, generic entrants and past legal disputes have shaped strategy; these factors may influence future revenue and volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
